Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.

Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA.

Neuropharmacology. 2013 Jan;64:254-63. doi: 10.1016/j.neuropharm.2012.07.017. Epub 2012 Jul 21.

PMID:
22824189
2.

Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity.

Russo E, Citraro R, Davoli A, Gallelli L, Di Paola ED, De Sarro G.

Neuropharmacology. 2013 Jan;64:371-9. doi: 10.1016/j.neuropharm.2012.06.039. Epub 2012 Jul 2. Review.

PMID:
22766393
3.

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Bishara D, Taylor D.

Drugs. 2008;68(16):2269-92. doi: 10.2165/0003495-200868160-00002. Review.

PMID:
18973393
4.

Conditioned avoidance response in the development of new antipsychotics.

Wadenberg ML.

Curr Pharm Des. 2010 Jan;16(3):358-70. Review.

PMID:
20109144
5.

The role of serotonin receptors in the action of atypical antipsychotic drugs.

Meltzer HY, Massey BW.

Curr Opin Pharmacol. 2011 Feb;11(1):59-67. doi: 10.1016/j.coph.2011.02.007. Epub 2011 Mar 21. Review.

PMID:
21420906
6.

Drugs in development for the treatment of schizophrenia.

Emsley R.

Expert Opin Investig Drugs. 2009 Aug;18(8):1103-18. doi: 10.1517/13543780903066756. Review.

PMID:
19589093
7.

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

Meltzer HY, Huang M.

Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Review.

PMID:
18772033
8.

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.

Meltzer HY, Massey BW, Horiguchi M.

Curr Pharm Biotechnol. 2012 Jun;13(8):1572-86. Review.

PMID:
22283753
9.

Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target.

Barak S, Weiner I.

Pharmacol Biochem Behav. 2011 Aug;99(2):164-89. doi: 10.1016/j.pbb.2011.03.011. Epub 2011 Mar 21. Review.

PMID:
21420999
10.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
11.

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK.

Pharmacol Ther. 2010 Dec;128(3):419-32. doi: 10.1016/j.pharmthera.2010.07.004. Epub 2010 Aug 10. Review.

PMID:
20705091
12.

On the trail of a cognitive enhancer for the treatment of schizophrenia.

Stip E, Chouinard S, Boulay LJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):219-32. Epub 2005 Jan 16. Review.

PMID:
15694228
13.

Preclinical behavioral models for predicting antipsychotic activity.

Castagné V, Moser PC, Porsolt RD.

Adv Pharmacol. 2009;57:381-418. doi: 10.1016/S1054-3589(08)57010-4. Epub 2009 Nov 27. Review.

PMID:
20230767
14.

Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions.

Shimizu S, Mizuguchi Y, Ohno Y.

CNS Neurol Disord Drug Targets. 2013 Sep;12(6):861-9. Review.

PMID:
23844689
15.

Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.

Meltzer HY, Rajagopal L, Huang M, Oyamada Y, Kwon S, Horiguchi M.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2181-94. doi: 10.1017/S1461145713000928. Review.

PMID:
24099265
16.

Animal models for predicting the efficacy and side effects of antipsychotic drugs.

Gobira PH, Ropke J, Aguiar DC, Crippa JA, Moreira FA.

Rev Bras Psiquiatr. 2013;35 Suppl 2:S132-9. doi: 10.1590/1516-4446-2013-1164. Review.

17.

Potential serotonergic agents for the treatment of schizophrenia.

Garay RP, Bourin M, de Paillette E, Samalin L, Hameg A, Llorca PM.

Expert Opin Investig Drugs. 2016;25(2):159-70. doi: 10.1517/13543784.2016.1121995. Epub 2015 Dec 15. Review.

PMID:
26576669
18.

[Blonanserin in the treatment of schizophrenia].

Tenjin T, Miyamoto S.

Nihon Rinsho. 2013 Apr;71(4):660-5. Review. Japanese.

PMID:
23678596
19.

Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.

Gross G, Wicke K, Drescher KU.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):155-66. doi: 10.1007/s00210-012-0806-3. Epub 2012 Nov 6. Review.

PMID:
23128852
20.

Drug safety and efficacy evaluation of sertindole for schizophrenia.

Karamatskos E, Lambert M, Mulert C, Naber D.

Expert Opin Drug Saf. 2012 Nov;11(6):1047-62. doi: 10.1517/14740338.2012.726984. Epub 2012 Sep 19. Review.

PMID:
22992213

Supplemental Content

Support Center